Research & Reviews: Journal of Medical and Health Sciences

e-ISSN:2319-9865
p-ISSN:2322-0104

Current Advancement: Alzheimer's Disease

Nisha Dhama[1]*, Nitika Sharma[1] and Aditya Thotakura[2]

[1]Department of Biotechnology, Meerut Institute of Engineering Technology, Meerut, India
[2]Al-Ameer College of Engineering, Visakhapatnam, India

Review Article

Received date: 10/09/2016
Accepted date: 11/09/2016
Published date: 17/09/2016

***For Correspondence**

Nisha Dhama, Department of Biotechnology, Meerut Institute of Engineering Technology, Meerut, Tel: 8897465898.

E-mail: nishadhama1@gmail.com

Keywords: Advancing age, Alzheimer's disease, Cognitive dysfunction, Dementia, Neuropsychological testing, Primary neuronal degeneration.

ABSTRACT

Alzheimer's disease (AD) is the primary open type of dementia in developed individuals, and an imperative issue to patients, parental figures and the social insurance framework. It is an inexorably noteworthy general wellbeing issue; with the quantity of individuals living with AD anticipated to increment drastically throughout the following couple of decades, making the quest for medicines and apparatuses to quantify ailment movement progressively critical. This audit depends on an inquiry of Medline, the Cochrane Database of Systemic Reviews, and reference arrangements of important productions. The subject headings and catchphrases utilized were Alzheimer's disease, dementia, essential neuronal degeneration and feeble infections. Just the articles written in English were incorporated. The conclusion is still essentially made considering history and physical and neurologic examinations. Endorsed medications are few and of constrained viability, serving generally to moderate or postpone movement and not to cure the illness, regardless of huge examination by pharmaceutical ventures. Cholinesterase inhibitors offer some assistance in treating psychological and worldwide working, and additionally behavioral variations from the norm in patients with mellow, moderate or serious stage sickness. The N-methyl-d-aspartate (NMDA) opponent, memantine, is likewise compelling alone or in mix with cholinesterase inhibitors in moderate to serious phases of the disease. Late bits of knowledge into the pathophysiology of AD have prompted promising investigational treatments, including the improvement of γ-and β-secretase inhibitors and dynamic and uninvolved vaccination against the amyloid β-protein.

INTRODUCTION

Alzheimer's disease (AD) is named after a German doctor, Alois Alzheimer, who initially portrayed it in the mid-20th century [1]. It has quickly risen as a noteworthy general wellbeing issue all through the world. It is evaluated to be by a wide margin the most well-known type of dementia in the United States, as of now harassing more than 5 million individuals, basically elderly people, with a related medicinal services cost in overabundance of US$100 billion every year [2]. The expense of watching over those harassed is tremendous and most presumably past the capacity of most creating nations, including Nigeria. A general meaning of dementia is an obtained disintegration of intellectual capacity that weakens one's capacity to effectively perform exercises of day by day living (ADLs). Memory loss most remarkably portrays it, and expanding age is its single most essential danger element [3]. Memory loss and dementia, by and large, are dynamic and irreversible, however the rate of movement is exceedingly variable and difficult to anticipate [3].

Epidemiology and Genetics

Advancing age is the absolute most real hazard variable for AD, with the predominance multiplying at regular intervals between the ages of 65 and 95 years and expanding from 2% at 65 years old to 40% at more than 85 years old [4]. While individuals do encounter minor changes in their memory and deduction as they age, these progressions don't influence day by day working or the capacity to live autonomously. Even though the disease has been accounted for to happen in exceedingly uncommon patients in their 20s and 30s, onset of clinical side effects in this sickness is remarkable until the 50s [5]. The second significant danger element for AD is family history, with a triple to fourfold higher danger among people having a solitary first-degree relative with AD and an about eightfold higher danger among people with two or more first-degree relatives with AD [5].

e-ISSN:2319-9865
p-ISSN:2322-0104

conversely late-onset AD, early-onset AD is generally uncommon, influencing just 5% of AD patients and creating in people 30-60 years old [5]. Some instances of early-onset AD, named familial AD, are acquired in an autosomal predominant way, with hereditary transformations on chromosomes 21, 14 and 1, bringing about the arrangement of irregular forerunner proteins, presenilin 1 (PS-1) and presenilin 2 (PS-2). The presenilin have been found to work in a mind boggling that demonstrations practically as γ-secretase [6]. Specifically, a couple of dozen families have transformations in the amyloid forerunner protein (APP) quality, for the most part in the locale of the quality that codes for the β-amyloid proteins [7]. Increased levels of β-amyloid have been found in AD patients with PS-1 or PS-2 transformations [8]. Apolipoprotein E (ApoE) quality status on chromosome 19 has all the earmarks of being a noteworthy hereditary powerlessness hazard element for the improvement of run of the mill late-onset AD [9]. Some confirmation recommends that e2 is defensive as respects the danger for AD. The putative system fundamental this component is as of now not caught on. There has all the earmarks of being a racial impact and conceivable quality natural collaboration with respect to ApoE and AD on the grounds that ApoE e4 demonstrated a frail relationship in African-Americans and did not have a relationship in Nigerians [10-12].

Other conceivable danger variables for AD incorporate sex, instruction, head injury, memory shortfall with seriousness of any degree, and little hippocampal volume. The vast Women's Health Initiative Memory Study of estrogen in elderly ladies has demonstrated that estrogen substitution may increment, instead of decline, the danger for AD [13,14]. Several studies demonstrate that absence of training is likewise a danger component for AD or on the other hand, instruction may bestow a "subjective store" that defers the onset of clinical appearances of AD [15]. Studies have been tangled by wide contrasts in reported arrangement in the criteria connected to characterize noteworthy head injury history. Further, ApoE e4 patients have been shown to recuperate less well from head injury, so the more noteworthy indications of injury might be a pseudo-marker for ApoE e4 legacy, which is a danger component for AD [16]. An abundance of information from different studies has recommended that a solid relationship between the metabolic disorder and vascular danger components seems to build the danger for AD [17]. Specifically, diabetes mellitus, insulin resistance, elevated cholesterol, hypertension, decreased activity, and corpulence are all danger components with some relationship for AD [18,19]. There is some fortuitous confirmation connecting aluminum with AD; [20,21]. no causal relationship has yet been built up and, considering the increasing experimental proof, the likelihood of such a relationship is turning out to be progressively unbelievable [22].

Neuropathology and Pathophysiology

Dementia is causally connected with disturbance of cerebral neuronal circuits, with the sum and area of neuronal loss bringing about its trademark symptomatology. Loss of bigger neurons of the shallow cortex is a reliable component of AD, as are synaptic adjustments, for example, decrease of pre-synaptic terminal thickness [23]. The neurotransmitter acetylcholine (Ach) seems, by all accounts, to be especially vital for memory, and loss of cholinergic neurons may underlie memory loss in AD [24]. Anatomically, AD starts in the entorhinal cortex and advances to the hippocampus and the back fleeting and parietal neocortex, eventually bringing about diffuse degeneration all through the cerebral cortex. Horribly, diffuse decay of the cerebral cortex, reflecting loss and shrinkage of neurons portray AD, with coming about extension of the ventricles. Specifically, the hippocampus, part of the mesial worldly flap memory framework, is harmed and decayed in AD, even at the most punctual phases of the illness [25,26]. Microscopically, the two distinguishing components of AD are amyloid plaques and neurofibrillary tangles. Notwithstanding amyloid plaques, wispy aggregations of an intracellular proteomous material called neurofibrillary tangles (NFTs) are available. These are the cardinal elements initially depicted by Alzheimer 103 years back. The supposed "amyloid theory", which attributes a causative part in AD to irregular amyloid preparing and stores, remains the predominant model with respect to AD causation [27]. As AD advances, glutaminergic, noradrenergic, and serotonergic framework lacks create and have related to further intellectual weakening and/or behavioral variations from the norm. Restorative endeavors amid the most recent decades must a great extent concentrated on revising these neurotransmitter shortfalls, and some unassuming accomplishment in enhancing indications has been accomplished.

Presentation and Natural History

Memory loss, especially transient memory loss, is likewise the most well-known showing manifestation of AD. Longer-term memory is at first saved yet will in the end fall apart also with ailment movement. This is alluded to as Ribot's law of memory, yet this is just moderately valid, as it is hard to check the precision of antiquated recollections [28]. Impairment of intellectual capacity that somewhat meddles with the elements of day by day living is portrayed as mellow psychological weakness (MCI), and numerous people with MCI will advance to AD dementia; the movement rate is around 12% every year [5], with quicker movement in a few subgroups, e.g. those with serious memory shortages particularly when extra subjective hindrance is likewise present. Behavioral changes and psychiatric side effects are not unprecedented in AD, particularly in the more propelled phases of the illness [29]. These incorporate unsettling, neurosis, psychosis, daydreams, tension and a sleeping disorder. Much of the time reported rest unsettling influences incorporate evening arousing, early morning arousing; intemperate daytime lethargy and on uncommon events, a diurnal inversion of rest wake cycle with the principle rest period happening in the daytime [30]. AD is dynamic and stays serious and eventually it is deadly, with death commonly happening 4-6 years after introductory analysis.

Diagnosis: Clinical, Pathologic and Radiologic Diagnosis

The most usually utilized clinical criteria for the analysis of AD are those of the Diagnostic Manual of Mental Disorders, Fourth

e-ISSN:2319-9865
p-ISSN:2322-0104

Edition (DSM-IV) [31] and those created in 1984 by a joint team on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) [32]. Normally, a neuropsychological examination investigates top to bottom an individual's execution in an extensive variety of useful spaces. Different screening tests and batteries have been produced amid the most recent years, however the Mini Mental State Examination (MMSE) is still the most generally utilized, in spite of its shortcoming with regards to identifying gentle dementia. The Community Screening Instrument for Dementia (CSI-D) was produced as a screening instrument for dementia for use in culturally diverse studies. It is made out of the accompanying capacity areas: dialect expression (naming, definition, reiteration and familiarity), enlistment, consideration and figuring, review, introduction to place and time, dialect perception (engine reaction), memory review, memory and praxis. It was produced from existing psychological screening instruments with a perspective to distinguishing things that were similarly separating for subjects with high and low levels of instruction and proficiency and for subjects from created and less created groups. The instrument has been utilized and accepted as a part of Cree American Indians, Nigerians in Ibadan, African Americans in Indianapolis [33] and among Chinese [34,35]. The CSI-D very associated with the Mini Mental State Examination (MMSE) and 10-word-list-learning undertaking [35].

The general neurologic examination may regularly be ordinary in the unhinged patient with AD. Proceeding with walk issues can happen in the late phases of AD, prompting generously expanded danger for falls. There is right now no research center test to affirm the finding of AD. The predominant neuropathologic criteria for AD are those declared by the National Institute on Aging (NIA) and National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) [36]. These criteria incorporate negligible neocortical plaque densities that are age-balanced however don't determine either the plaque sort or the neocortical locale included. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria requires an age-balanced semi-quantitative plaque recurrence and a clinical finding of dementia for the analysis of AD [37].

Both DSM-IV-Text Revision (DSM-IV-TR) and NINCDS-ADRDA criteria depend vigorously on history and the neurologic examination, and late proof proposes that both have fallen behind because of the late emotional advances in our logical information of AD, with solid biomarkers accessible now being founded on auxiliary Magnetic Resonance Imaging (MRI), atomic imaging with Positron Emission Tomography (PET) and cerebrospinal liquid (CSF) investigations [38]. Although the changed NINCDS-ADRDA criteria stay concentrated on a clinical assurance of memory disability, they additionally stipulate that there must likewise be no less than one irregular biomarker among basic neuroimaging with MRI, atomic neuroimaging with PET and CSF examination of β-amyloid or tau proteins [38]. Structural MRI in patients with AD or MCI indicates decay in the entorhinal cortex and hippocampus, prescient of future intellectual decrease and transformation to AD among people with MCI. It has been proposed, in this way, that MRI volumetry might be a helpful imaging subordinate in the analysis of AD and may even surpass the indicative exactness of clinical assessment [39,40]. PET-based imaging incorporates estimation of provincial cerebral glucose digestion system (rCMRgic) utilizing the halfway metabolized glucose simple fluorine-18 (18 F)- marked 2-fluoro-2-deoxy-d-glucose (FDG). FDG-PET cerebrum pictures in AD are described by huge local hypo metabolism. A diminishment of glucose digestion system in the respective transient, parietal and back cingulated district is as of now the most ordinarily depicted demonstrative standard for AD. The utilization of radiotracers other than FDG, including carbon-11 (11 C)- named tracers, is expanding the materialness of PET to the study and analysis of dementia and psychiatric sicknesses for the most part [41]. PET imaging tracers which name and accordingly permit representation of β-amyloid or tau (t) protein in vivo are promising ways to deal with enhancing the early determination of AD. PET ligands for plaque imaging are all gotten from histological recoloring operators and in view of the positive clinical results to date; β-amyloid imaging specialists will probably enter stage III assessment and more extensive clinical use sooner rather than later [1]. PET will most likely keep on being vital in dementia research and progressively imperative in clinical practice as new molecularly focused on radiotracers are affirmed for clinical use.

Treatment

Over a hundred years after its disclosure, AD stays serious and its movement unavoidable, with the essential centre of treatment on alleviation of related behavioral and neurologic issues. At present no treatment has been demonstrated to defer natural movement of illness. The improvement of medications that will postpone sickness movement in influenced people or fundamentally keep its onset in typical more established subjects remains a vital, however far subtle objective [42]. The as of now accessible symptomatic treatments for AD gently enhance absconds in psychological capacity, ADLs and worldwide working, and postpone onset of or somewhat enhance behavioral indications [43]. The part of relatives or different parental figures is basic, and any advantages should be weighed against unfavorable impacts that may happen in deciding a proper dosage or choosing whether to proceed with treatment with a specific medication [44]. Memory helps, for example, note pads and posted day by day updates might be useful in the early phases of the infection. The patient's home, particularly the kitchen and bathrooms, must be made as sheltered as could be expected under the circumstances, and in the end patients must quit driving and can never again be in charge of their accounts and other individual undertakings.

Various medications have been endorsed for treatment of AD, but they are not therapeutic. The current pharmacologic treatments for AD can be extensively partitioned into two classifications: (1) symptomatic methodologies considering upgrade of neurotransmitter frameworks and (2) neuroprotective systems utilizing cancer prevention agents, for example, vitamin E. Numerous AD patients likewise are recommended antipsychotics or antidepressants to oversee psychiatric and behavioral manifestations, however with an evidently expanded danger of mortality [29].

e-ISSN:2319-9865
p-ISSN:2322-0104

The best drugs for AD to date are the acetylcholinesterase (AChE) inhibitors, which diminish the enzymatic debasement of the neurotransmitter Ach, insufficient in the AD mind, and in this way upgrade the cholinergic framework. The three AChE inhibitors affirmed by the United States Food and Drug Administration (FDA) for treatment of AD, donepezil, galantamine and rivastigmine, have been shown to enhance cognizance, capacity in ADL and conduct in patients with AD in twofold visually impaired, fake treatment controlled trials [42,45]. Despite the observation among clinicians of restricted remedial adequacy and cost-viability of AChE inhibitors, this class of medications is quite successful in ahead of schedule (i.e., gentle to direct) AD as far as symptomatic control and postpone of its long haul unfavourable impacts [46,47].

Memantine is a N-methyl-d-aspartate (NMDA) receptor adversary likewise affirmed for use in AD and was the principal drug endorsed for treatment of moderate to extreme AD [48]. Although its system of activity is not by any stretch of the imagination comprehended, it works by offending glutamate at the NMDA receptor, possibly enhancing signal transmission, and by forestalling overabundance calcium to hurry into the neurons with glutamate incitement, and may thusly secure against poisonous harm to cholinergic neurons. In a study, patients with moderate to serious AD treated with memantine alone indicated noteworthy change in intellectual capacity and ADLs in a fake treatment controlled trial [49]. In another clinical investigation of patients with moderate to extreme AD, memantine in blend with the AChE inhibitors (donepezil, galantamine, or rivastigmine) essentially impeded decay in both psychological capacity and ADLs contrasted with patients treated with fake treatment or AChE inhibitors alone [49].

Evidence against Previously Accepted Therapies

In view of proof that free radicals may add to the pathologic procedures in AD, cell reinforcements, for example, α-tocopherol (vitamin E) and selegiline are being assessed for its treatment. Results to date have been obscure [50]. However, home grown supplements are regularly utilized by AD patients, most outstandingly, Ginkgo biloba, whose implied pharmacologic impact is likely due to flavoglycoside, a free-radical scrounger and cancer prevention agent [29]. Several two-fold visually impaired, fake treatment controlled studies with negative results contend against the utilization of estrogen or non-steroidal calming drugs, both of which may really have more serious dangers than advantages in subjects with AD [51,52].

Treatment of Behavioral Symptoms

Treatment of these side effects can test, and none of the as of now accessible medications is affirmed by the United States FDA for treating behavioral indications in AD. Treatment of behavioral manifestations is of extraordinary significance to relatives and parental figures on the grounds that these indications have a tendency to be most troublesome for them to oversee. Risperidone and olanzapine are compelling for the treatment of hostility in AD. Specific serotonin reuptake inhibitors, albeit all around endured, are just unassumingly viable for the administration of behavioral issues and ought to be utilized at lower measurements to maintain a strategic distance from unfavourable impacts. A sleeping disorder might be receptive to trazodone or alprazolam or different benzodiazepines.

Future Trends in AD Drug Therapy

Most efforts to create drugs that will defer disease movement have as of late centered around lessening amyloid and possibly ending or turning around development of plaques in the mind. Various new medications are presently being assessed clinically for security (stage I and IIA trials) and adequacy (stage IIB and - III trials) with accentuation on procedures to moderate the pathogenicity of β-amyloid [42]. Vaccination utilizing the β-amyloid protein demonstrated viable at first in diminishing β-amyloid plaques in transgenic creatures, and a comparable immunization was tried in a huge stage II trial [53]. which was hindered when countless created encephalitis [54].

CONCLUSION

At present, there is a convincing need to set up novel medications for AD and examination into AD treatment has been at any rate halfway effective as far as creating symptomatic medicines, yet has additionally had a few disappointments as far as creating disease altering treatments. While progress has been frustratingly moderate in the improvement of powerful medicines for AD, comprehension of its fundamental science keeps on progressing and, with various promising treatments in the pipeline, there is space for some confidence.

REFERENCES

1. Manckoundia P, et al. Alterations in olfaction during Alzheimer disease, Parkinson disease and lewy body disease. J Alzheimers Dis Parkinsonism. 2016;6:274.
2. McLarnon JG. Chemokine interleukin-8 (IL-8) in Alzheimer's and other neurodegenerative diseases. J Alzheimers Dis Parkinsonism. 2016;6:273.
3. Choi H, et al. Interaction between amyloid beta toxicity and the PI3K pathway in Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:269.
4. Begum MM, et al. Anticholinesterase and antioxidant potentials of a medicinal plant *Abroma augusta*: Implications for the alternative treatment therapy of cognitive deficits in Alzheimer's disease. Clin Pharmacol Biopharm. 2015;4:148.

5. Mun MJ, et al. The genetic relationship between interleukin genes in Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:263.

6. Dumont C, et al. Psycho-educational approach in Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:261.

7. Uddin MS, et al. Searching the linkage between high fat diet and Alzheimer's disease: A debatable proof stand for ketogenic diet to alleviate symptoms of Alzheimer's patient with APOE ε4 Allele. J Neurol Neurophysiol. 2016;7:397.

8. Pogue AI et al. Natural and synthetic neurotoxins in our environment: From Alzheimer's disease (AD) to Autism spectrum disorder (ASD). J Alzheimers Dis Parkinsonism. 2016;6:249.

9. Yamazaki T, et al. Burden of vascular risk factors on the evolution of Alzheimer's disease: A longitudinal observational study. J Alzheimers Dis Parkinsonism. 2016;6:254.

10. Chua K, et al. A randomized controlled pilot trial of Chinese medicine (Di-Tan Decoction) in the treatment of Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:256.

11. Korrapati N, et al. Alzheimer's disease and memory loss - A review. J Alzheimers Dis Parkinsonism. 2016;6:259.

12. Martins IJ. Bacterial lipopolysaccharides change membrane fluidity with relevance to phospholipid and amyloid beta dynamics in Alzheimer's disease. J Microb Biochem Technol. 2016;8:322-324.

13. Liew H and Lee SH. Soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:271.

14. Abyad A. Alzheimer's the road ahead in the Middle East. J Alzheimers Dis Parkinsonism. 2016;6:241.

15. Ali AA, et al. Comparative study on the influence of epigallocatechin-3-gallate and/or coenzyme Q10 against Alzheimer's disease induced by aluminium in normally-fed and protein malnourished rats. J Alzheimers Dis Parkinsonism. 2016;6:240.

16. Gelbard A. Glucose role in treatment of Alzheimer's disease. J Gerontol Geriatr Res. 2016;5:334.

17. Szot P. Elevated cerebrospinal fluid norepinephrine in the elderly can link depression and a reduced glymphatic system as risk factors for Alzheimer's disease. J Aging Sci. 2016;4:158.

18. Nagae T, et al. Cytokines and cytokine receptors involved in the pathogenesis of Alzheimer's disease. J Clin Cell Immunol. 2016;7:441.

19. Uddin MS, et al. Neuroprotective activity of *Asparagus racemosus* Linn. against ethanol-induced cognitive impairment and oxidative stress in rats brain: Auspicious for controlling the risk of Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:245.

20. Dong Y, et al. Synthesis, biological evaluation and molecular modeling of (E)-3-Propargylene-1, 3-Dihydro-2H-Indol-2-Ones as Acetyl- and butyryl cholinesterase inhibitors for the treatment of Alzheimer's disease. Med chem. 2016;6:372-376.

21. Funicello M, et al. Heterocycles for Alzheimer disease: 4- and 5-substituted benzothiophenes as starting scaffold in the construction of potential new inhibitors of BACE 1. Med chem. 2016;6:377-384.

22. Garcia-Sierra F. Commentary on ubiquitin is associated with early truncation of tau protein at aspartic acid 421 during the maturation of neurofibrillary tangles in Alzheimer's disease. J Med Surg Pathol. 2016;1:121.

23. Jester H and Al-Achi A. Does the Mediterranean diet or botanicals influence Alzheimer's disease? Clin Pharmacol Biopharm. 2016;5:e123.

24. Archer T. Amelioration of symptoms and biomarkers of Alzheimers disease by physical exercise. Open access. 2016;2:e105.

25. Brookes K, et al. Identifying polymorphisms in the Alzheimer's related APP gene using the minion sequencer. Next Generat Sequenc & Applic. 2016;3:125.

26. Ajami S, et al. Role of Alzheimer disease national registry system in prevention and treatment management. J Bioeng Biomed Sci. 2016;6:188.

27. Melamed I. Alzheimer's disease of the immune system: A new variant of immune deficiency. Immunother Open Acc 2016;2:115.

28. Bambo MP, et al. Retinal and optic disc alterations in Alzheimer's disease: The eye as a potential central nervous system window. J Alzheimers Dis Parkinsonism. 2016;6:223.

29. Kljajevic V. An emerging model of word retrieval in preclinical Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:225.

30. Cifuentes D, et al. Targeting hypertension to manage Alzheimer's disease: Rational and promise. J Alzheimers Dis Parkinsonism. 2016;6:228.

31. Dessouky MM and Elrashidy MA. Feature extraction of the Alzheimer's disease images using different optimization algorithms. J Alzheimers Dis Parkinsonism. 2016;6:230.

e-ISSN:2319-9865
p-ISSN:2322-0104

32. Cacabelos R. Epigenetics of brain disorders: The paradigm of Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:229.
33. Wu Y, et al. Observation study of the retina with the Alzheimer's disease or amnestic mild cognitive impairment Patients. J Clin Exp Ophthalmol. 2016;7:545.
34. Shinno H, et al. Alterations in rapid eye movement sleep parameters predict for subsequent progression from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:218.
35. Suzuki N, et al. Cellular transplantation as the treatment of Alzheimer's disease in mouse models. J Alzheimers Dis Parkinsonism; 2016;6:219.
36. Zerovnik E, et al. Recent developments in treating Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:220.
37. Allen HB, et al. Alzheimers disease: A novel hypothesis for the development and the subsequent role of beta amyloid. J Neuroinfect Dis. 2016;7:211.
38. Woods JJ, et al. Cigarette smoking: A causal factor for Alzheimer's disease? JGerontol Geriatr Res. 2016;5:286.
39. Biswas A and Das SK. Alzheimer and Parkinson's disease -Two faces of the same disease? J Alzheimers Dis Parkinsonism. 2016;6:222.
40. Singh A and Kumar A. A comparative analysis of intrahippocampal amyloid beta (1-42) and intracerbroventricular streptozotocin models of alzheimer's disease: possible behavioral, biochemical, mitochondrial, cellular and histopathological evidences. J Alzheimers Dis Parkinsonism. 2016;6:208.
41. Narayan M, et al. Identification of novel Cdc37 interacting proteins and pathways in human Alzheimer's disease brain tissue using mass spectrometry. J Data Mining Genomics & Proteomics. 2016;7:193.
42. Zhang X, et al. Is the combination/multi-target therapy a new promise for Alzheimer's disease? J Alzheimers Dis Parkinsonism. 2016;6:216.
43. Shinno H, et al. Effect of yokukansan, a traditional herbal prescription, on sleep disturbances in patients with Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:215.
44. Passafiume D, et al. Recognition of environmental emotional sounds in Alzheimer's disease. J Alzheimers Dis Parkinsonism. 2016;6:217.
45. Hussain G, et al. Synthesis and molecular docking study of some new 4-{[4-(2-Furoyl)-1-piperazinyl]methyl}-N-(substituted-phenyl)benzamides as possible therapeutic entrants for Alzheimer's disease. Med chem. 2016;6:129-136.
46. Perez A, et al. The rationale of using coffee and melatonin as an alternative treatment for Alzheimer's disease. j Alzheimer's dis parkinsonism. 2016;6:205.
47. Lavano A, et al. Deep brain stimulation for Alzheimer's disease. Brain Disord Ther. 2016;5:202.
48. Bostancikliıoglu M. Anti-Aβ antibodies in the fighting with Alzheimer's disease. Single Cell Biol. 2016;5:127.
49. Gottschalk WK, et al. The role of upregulated APOE in Alzheimer's disease etiology. J Alzheimers Dis Parkinsonism. 2016;6:209.
50. Valencic M. Excessive blood preassure lowering: possible cause of Alzheimer's disease. J Gerontol Geriatr Res. 2016;5:265.
51. Sourdet S, et al. Effectiveness of a specific care plan in alzheimer's disease in the oldest old. J Alzheimers Dis Parkinsonism. 2015;5:194.
52. Benussi A, et al. Transcranial magnetic stimulation in alzheimer's disease and cortical dementias. J Alzheimers Dis Parkinsonism. 2015;5:197.
53. Cintra MTG, et al. P300 Evoked potential and risk of mild cognitive impairment progression to Alzheimer's dementia: A literature review. J Neurol Neurophysiol. 2015;6:322.
54. Zhang Q, et al. Alzheimer's model develops early ADHD syndrome. J Neurol Neurophysiol. 2015;6:329.